Frontiers in Endocrinology-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1218440, encodeId=dedb12184408c, content=审稿速度:1.0 偏重的研究方向：糖尿病 经验分享：请问各位大神，4月1号投，4.20邮件发过来说第1个审稿人意见上传了，提了十条意见，评分4345。说等第2个审稿人意见才能在系统上修改，目前一直没有第2个审稿人意见。有人类似吗？下一步该催稿还是等？<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=258, replyNumber=32, topicName=null, topicId=null, topicList=[TopicDto(id=76652, encryptionId=4f77e665253, topicName=糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0efd5705923, createdName=ms5000001229631335, createdTime=Tue May 10 13:46:10 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199310, encodeId=c0bc119931057, content=偏重的研究方向：糖尿病 经验分享：各位大佬我想问一下上个月投稿了该杂志状态一直都是“Your manuscript has been submitted and is now in the editorial assignment stage. We are in the process of appointing an editor and reviewers.”始终没有分配编辑，这种情况正常吗？或许该不该催一下呢？<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a><a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a><a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=526, replyNumber=16, topicName=null, topicId=null, topicList=[TopicDto(id=76652, encryptionId=4f77e665253, topicName=糖尿病), TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习), TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220304/ec265085fc77472b994925ad492adddb/3675981d0d3549d7b0fecbaa57f44ce0.jpg, createdBy=dbca6432415, createdName=ms8000000593527714, createdTime=Fri Mar 04 09:48:06 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220790, encodeId=4c6d1220e903b, content=偏重的研究方向：内分泌;Endocrinology 经验分享：大家好请问家人们在 initial validation等待了多久哈 4.27投稿等到现在还在这一步正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=234b5498982, createdName=ms6000001522264603, createdTime=Wed May 18 22:34:10 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177288, encodeId=34aa21e728837, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：有人碰到过这种拒稿理由吗？投稿过程中唯一异常的地方是杂志要求把原始数据上传到公共数据平台，我选择的暂未上传，不知道是不是因为这个原因被拒稿，按理说原始数据链接可以后面再补上，不造是不是变相拒稿。。。。。 2023.12.14 submit 2023.12.19 reject The reason for this decision is: Ethical issues or Integrity concerns, or other breach of policy were identified in this manuscript that prevent further review or publication., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db655482134, createdName=ms2000000984739514, createdTime=Tue Dec 26 15:07:37 CST 2023, time=2023-12-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1186886, encodeId=890311868868e, content=审稿速度:2.0 | 投稿命中率:50.0 | 版面费用:18000.0 经验分享： Date Updates 21 Jan 2022 Article accepted for publication. 20 Jan 2022 Review of Review Editor 1 finalized. 07 Jan 2022 Review of Review Editor 2 finalized. You posted new comments. You posted new comments. Associate Editor Terry Francis Davies reactivated the review of Review Editor 2. Associate Editor Terry Francis Davies reactivated the review of Review Editor 1. 06 Jan 2022 Review of Review Editor 2 finalized. Submitting Author re-submitted manuscript. 19 Dec 2021 Interactive review forum activated automatically. 02 Dec 2021 Review of Reviewer 1 is finalized. 16 Nov 2021 Submitting Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d5d45263398, createdName=Q.Aur., createdTime=Fri Jan 21 16:59:27 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095540, encodeId=db20209554054, content=最近太慢了，最后一步，都快一个月了，杂志社放假了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c84b1734099, createdName=1def4ad2m75(暂无匿称), createdTime=Sun Oct 23 16:22:06 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106133, encodeId=be1a210613317, content=审稿速度:1.0 偏重的研究方向：糖尿病 经验分享：为什么我先被接受了，钱都交了，然后被拒了啊………… This manuscript does not fulfill the standards established for the journal to be considered for publication, and according to Frontiers policies (https://www***ontiersin.org/guidelines/policies-and-publication-ethics#AuthorshipAuthorResponsibilities), the article is being rejected. This decision applies across all Frontiers journals and is final., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKa9zsBsxXW560WZZQCmZVjdWtyppuKqGNgErY8TwOXAMx9Q53X4PRT2QdmNuTvHyJfzcicyDNqMUQ/132, createdBy=8bfe5305985, createdName=大仑丁, createdTime=Thu Dec 15 07:13:07 CST 2022, time=2022-12-15, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1077238, encodeId=441610e7238aa, content=偏重的研究方向：临床 经验分享：请问各位，一审两个审稿人提了一些小问题，但均直接endorse了，现在review finalized六天了，请问我能催下吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=969f5129926, createdName=1465389cm38暂无昵称, createdTime=Mon Dec 06 07:57:57 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974605, encodeId=f03a9e460516, content=审稿速度:2.0 经验分享：现在Frontiers都这么慢了吗，那比非OA的还有什么优势？6月9日投稿，到6月18还没有分配编辑……请问大家都是多久分配编辑呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7a851992297, createdName=1e1a9f0am26(暂无匿称), createdTime=Fri Jun 18 09:50:06 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882877, encodeId=20888828e745, content=我的一篇投稿frongtier in endocri，审了一个月回来了，两个reviewer，一个REVIEW 建议 substantial revision, 一个建议发表，这个substantial revision 是major 的意思吗？还是大大修？这种分歧很大的修完后接受的几率有多大？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92de2526374, createdName=124eece7m49(暂无昵称), createdTime=Sat Sep 05 08:09:33 CST 2020, time=2020-09-05, status=1, ipAttribution=)]

2022-05-10 ms5000001229631335

审稿速度:1.0
偏重的研究方向：糖尿病
经验分享：请问各位大神，4月1号投，4.20邮件发过来说第1个审稿人意见上传了，提了十条意见，评分4345。说等第2个审稿人意见才能在系统上修改，目前一直没有第2个审稿人意见。有人类似吗？下一步该催稿还是等？#糖尿病#

258 32

展开32条回复

[GetPortalCommentsPageByObjectIdResponse(id=1218440, encodeId=dedb12184408c, content=审稿速度:1.0 偏重的研究方向：糖尿病 经验分享：请问各位大神，4月1号投，4.20邮件发过来说第1个审稿人意见上传了，提了十条意见，评分4345。说等第2个审稿人意见才能在系统上修改，目前一直没有第2个审稿人意见。有人类似吗？下一步该催稿还是等？<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=258, replyNumber=32, topicName=null, topicId=null, topicList=[TopicDto(id=76652, encryptionId=4f77e665253, topicName=糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0efd5705923, createdName=ms5000001229631335, createdTime=Tue May 10 13:46:10 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199310, encodeId=c0bc119931057, content=偏重的研究方向：糖尿病 经验分享：各位大佬我想问一下上个月投稿了该杂志状态一直都是“Your manuscript has been submitted and is now in the editorial assignment stage. We are in the process of appointing an editor and reviewers.”始终没有分配编辑，这种情况正常吗？或许该不该催一下呢？<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a><a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a><a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=526, replyNumber=16, topicName=null, topicId=null, topicList=[TopicDto(id=76652, encryptionId=4f77e665253, topicName=糖尿病), TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习), TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220304/ec265085fc77472b994925ad492adddb/3675981d0d3549d7b0fecbaa57f44ce0.jpg, createdBy=dbca6432415, createdName=ms8000000593527714, createdTime=Fri Mar 04 09:48:06 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220790, encodeId=4c6d1220e903b, content=偏重的研究方向：内分泌;Endocrinology 经验分享：大家好请问家人们在 initial validation等待了多久哈 4.27投稿等到现在还在这一步正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=234b5498982, createdName=ms6000001522264603, createdTime=Wed May 18 22:34:10 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177288, encodeId=34aa21e728837, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：有人碰到过这种拒稿理由吗？投稿过程中唯一异常的地方是杂志要求把原始数据上传到公共数据平台，我选择的暂未上传，不知道是不是因为这个原因被拒稿，按理说原始数据链接可以后面再补上，不造是不是变相拒稿。。。。。 2023.12.14 submit 2023.12.19 reject The reason for this decision is: Ethical issues or Integrity concerns, or other breach of policy were identified in this manuscript that prevent further review or publication., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db655482134, createdName=ms2000000984739514, createdTime=Tue Dec 26 15:07:37 CST 2023, time=2023-12-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1186886, encodeId=890311868868e, content=审稿速度:2.0 | 投稿命中率:50.0 | 版面费用:18000.0 经验分享： Date Updates 21 Jan 2022 Article accepted for publication. 20 Jan 2022 Review of Review Editor 1 finalized. 07 Jan 2022 Review of Review Editor 2 finalized. You posted new comments. You posted new comments. Associate Editor Terry Francis Davies reactivated the review of Review Editor 2. Associate Editor Terry Francis Davies reactivated the review of Review Editor 1. 06 Jan 2022 Review of Review Editor 2 finalized. Submitting Author re-submitted manuscript. 19 Dec 2021 Interactive review forum activated automatically. 02 Dec 2021 Review of Reviewer 1 is finalized. 16 Nov 2021 Submitting Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d5d45263398, createdName=Q.Aur., createdTime=Fri Jan 21 16:59:27 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095540, encodeId=db20209554054, content=最近太慢了，最后一步，都快一个月了，杂志社放假了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c84b1734099, createdName=1def4ad2m75(暂无匿称), createdTime=Sun Oct 23 16:22:06 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106133, encodeId=be1a210613317, content=审稿速度:1.0 偏重的研究方向：糖尿病 经验分享：为什么我先被接受了，钱都交了，然后被拒了啊………… This manuscript does not fulfill the standards established for the journal to be considered for publication, and according to Frontiers policies (https://www***ontiersin.org/guidelines/policies-and-publication-ethics#AuthorshipAuthorResponsibilities), the article is being rejected. This decision applies across all Frontiers journals and is final., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKa9zsBsxXW560WZZQCmZVjdWtyppuKqGNgErY8TwOXAMx9Q53X4PRT2QdmNuTvHyJfzcicyDNqMUQ/132, createdBy=8bfe5305985, createdName=大仑丁, createdTime=Thu Dec 15 07:13:07 CST 2022, time=2022-12-15, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1077238, encodeId=441610e7238aa, content=偏重的研究方向：临床 经验分享：请问各位，一审两个审稿人提了一些小问题，但均直接endorse了，现在review finalized六天了，请问我能催下吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=969f5129926, createdName=1465389cm38暂无昵称, createdTime=Mon Dec 06 07:57:57 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974605, encodeId=f03a9e460516, content=审稿速度:2.0 经验分享：现在Frontiers都这么慢了吗，那比非OA的还有什么优势？6月9日投稿，到6月18还没有分配编辑……请问大家都是多久分配编辑呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7a851992297, createdName=1e1a9f0am26(暂无匿称), createdTime=Fri Jun 18 09:50:06 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882877, encodeId=20888828e745, content=我的一篇投稿frongtier in endocri，审了一个月回来了，两个reviewer，一个REVIEW 建议 substantial revision, 一个建议发表，这个substantial revision 是major 的意思吗？还是大大修？这种分歧很大的修完后接受的几率有多大？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92de2526374, createdName=124eece7m49(暂无昵称), createdTime=Sat Sep 05 08:09:33 CST 2020, time=2020-09-05, status=1, ipAttribution=)]

2022-03-04 ms8000000593527714

偏重的研究方向：糖尿病
经验分享：各位大佬我想问一下上个月投稿了该杂志状态一直都是“Your manuscript has been submitted and is now in the editorial assignment stage. We are in the process of appointing an editor and reviewers.”始终没有分配编辑，这种情况正常吗？或许该不该催一下呢？#糖尿病##学习##期刊论坛#

526 16

展开16条回复

[GetPortalCommentsPageByObjectIdResponse(id=1218440, encodeId=dedb12184408c, content=审稿速度:1.0 偏重的研究方向：糖尿病 经验分享：请问各位大神，4月1号投，4.20邮件发过来说第1个审稿人意见上传了，提了十条意见，评分4345。说等第2个审稿人意见才能在系统上修改，目前一直没有第2个审稿人意见。有人类似吗？下一步该催稿还是等？<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=258, replyNumber=32, topicName=null, topicId=null, topicList=[TopicDto(id=76652, encryptionId=4f77e665253, topicName=糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0efd5705923, createdName=ms5000001229631335, createdTime=Tue May 10 13:46:10 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199310, encodeId=c0bc119931057, content=偏重的研究方向：糖尿病 经验分享：各位大佬我想问一下上个月投稿了该杂志状态一直都是“Your manuscript has been submitted and is now in the editorial assignment stage. We are in the process of appointing an editor and reviewers.”始终没有分配编辑，这种情况正常吗？或许该不该催一下呢？<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a><a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a><a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=526, replyNumber=16, topicName=null, topicId=null, topicList=[TopicDto(id=76652, encryptionId=4f77e665253, topicName=糖尿病), TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习), TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220304/ec265085fc77472b994925ad492adddb/3675981d0d3549d7b0fecbaa57f44ce0.jpg, createdBy=dbca6432415, createdName=ms8000000593527714, createdTime=Fri Mar 04 09:48:06 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220790, encodeId=4c6d1220e903b, content=偏重的研究方向：内分泌;Endocrinology 经验分享：大家好请问家人们在 initial validation等待了多久哈 4.27投稿等到现在还在这一步正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=234b5498982, createdName=ms6000001522264603, createdTime=Wed May 18 22:34:10 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177288, encodeId=34aa21e728837, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：有人碰到过这种拒稿理由吗？投稿过程中唯一异常的地方是杂志要求把原始数据上传到公共数据平台，我选择的暂未上传，不知道是不是因为这个原因被拒稿，按理说原始数据链接可以后面再补上，不造是不是变相拒稿。。。。。 2023.12.14 submit 2023.12.19 reject The reason for this decision is: Ethical issues or Integrity concerns, or other breach of policy were identified in this manuscript that prevent further review or publication., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db655482134, createdName=ms2000000984739514, createdTime=Tue Dec 26 15:07:37 CST 2023, time=2023-12-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1186886, encodeId=890311868868e, content=审稿速度:2.0 | 投稿命中率:50.0 | 版面费用:18000.0 经验分享： Date Updates 21 Jan 2022 Article accepted for publication. 20 Jan 2022 Review of Review Editor 1 finalized. 07 Jan 2022 Review of Review Editor 2 finalized. You posted new comments. You posted new comments. Associate Editor Terry Francis Davies reactivated the review of Review Editor 2. Associate Editor Terry Francis Davies reactivated the review of Review Editor 1. 06 Jan 2022 Review of Review Editor 2 finalized. Submitting Author re-submitted manuscript. 19 Dec 2021 Interactive review forum activated automatically. 02 Dec 2021 Review of Reviewer 1 is finalized. 16 Nov 2021 Submitting Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d5d45263398, createdName=Q.Aur., createdTime=Fri Jan 21 16:59:27 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095540, encodeId=db20209554054, content=最近太慢了，最后一步，都快一个月了，杂志社放假了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c84b1734099, createdName=1def4ad2m75(暂无匿称), createdTime=Sun Oct 23 16:22:06 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106133, encodeId=be1a210613317, content=审稿速度:1.0 偏重的研究方向：糖尿病 经验分享：为什么我先被接受了，钱都交了，然后被拒了啊………… This manuscript does not fulfill the standards established for the journal to be considered for publication, and according to Frontiers policies (https://www***ontiersin.org/guidelines/policies-and-publication-ethics#AuthorshipAuthorResponsibilities), the article is being rejected. This decision applies across all Frontiers journals and is final., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKa9zsBsxXW560WZZQCmZVjdWtyppuKqGNgErY8TwOXAMx9Q53X4PRT2QdmNuTvHyJfzcicyDNqMUQ/132, createdBy=8bfe5305985, createdName=大仑丁, createdTime=Thu Dec 15 07:13:07 CST 2022, time=2022-12-15, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1077238, encodeId=441610e7238aa, content=偏重的研究方向：临床 经验分享：请问各位，一审两个审稿人提了一些小问题，但均直接endorse了，现在review finalized六天了，请问我能催下吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=969f5129926, createdName=1465389cm38暂无昵称, createdTime=Mon Dec 06 07:57:57 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974605, encodeId=f03a9e460516, content=审稿速度:2.0 经验分享：现在Frontiers都这么慢了吗，那比非OA的还有什么优势？6月9日投稿，到6月18还没有分配编辑……请问大家都是多久分配编辑呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7a851992297, createdName=1e1a9f0am26(暂无匿称), createdTime=Fri Jun 18 09:50:06 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882877, encodeId=20888828e745, content=我的一篇投稿frongtier in endocri，审了一个月回来了，两个reviewer，一个REVIEW 建议 substantial revision, 一个建议发表，这个substantial revision 是major 的意思吗？还是大大修？这种分歧很大的修完后接受的几率有多大？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92de2526374, createdName=124eece7m49(暂无昵称), createdTime=Sat Sep 05 08:09:33 CST 2020, time=2020-09-05, status=1, ipAttribution=)]

2022-05-18 ms6000001522264603

偏重的研究方向：内分泌;Endocrinology
经验分享：大家好请问家人们在 initial validation等待了多久哈 4.27投稿等到现在还在这一步正常吗

97 16

展开16条回复

[GetPortalCommentsPageByObjectIdResponse(id=1218440, encodeId=dedb12184408c, content=审稿速度:1.0 偏重的研究方向：糖尿病 经验分享：请问各位大神，4月1号投，4.20邮件发过来说第1个审稿人意见上传了，提了十条意见，评分4345。说等第2个审稿人意见才能在系统上修改，目前一直没有第2个审稿人意见。有人类似吗？下一步该催稿还是等？<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=258, replyNumber=32, topicName=null, topicId=null, topicList=[TopicDto(id=76652, encryptionId=4f77e665253, topicName=糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0efd5705923, createdName=ms5000001229631335, createdTime=Tue May 10 13:46:10 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199310, encodeId=c0bc119931057, content=偏重的研究方向：糖尿病 经验分享：各位大佬我想问一下上个月投稿了该杂志状态一直都是“Your manuscript has been submitted and is now in the editorial assignment stage. We are in the process of appointing an editor and reviewers.”始终没有分配编辑，这种情况正常吗？或许该不该催一下呢？<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a><a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a><a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=526, replyNumber=16, topicName=null, topicId=null, topicList=[TopicDto(id=76652, encryptionId=4f77e665253, topicName=糖尿病), TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习), TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220304/ec265085fc77472b994925ad492adddb/3675981d0d3549d7b0fecbaa57f44ce0.jpg, createdBy=dbca6432415, createdName=ms8000000593527714, createdTime=Fri Mar 04 09:48:06 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220790, encodeId=4c6d1220e903b, content=偏重的研究方向：内分泌;Endocrinology 经验分享：大家好请问家人们在 initial validation等待了多久哈 4.27投稿等到现在还在这一步正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=234b5498982, createdName=ms6000001522264603, createdTime=Wed May 18 22:34:10 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177288, encodeId=34aa21e728837, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：有人碰到过这种拒稿理由吗？投稿过程中唯一异常的地方是杂志要求把原始数据上传到公共数据平台，我选择的暂未上传，不知道是不是因为这个原因被拒稿，按理说原始数据链接可以后面再补上，不造是不是变相拒稿。。。。。 2023.12.14 submit 2023.12.19 reject The reason for this decision is: Ethical issues or Integrity concerns, or other breach of policy were identified in this manuscript that prevent further review or publication., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db655482134, createdName=ms2000000984739514, createdTime=Tue Dec 26 15:07:37 CST 2023, time=2023-12-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1186886, encodeId=890311868868e, content=审稿速度:2.0 | 投稿命中率:50.0 | 版面费用:18000.0 经验分享： Date Updates 21 Jan 2022 Article accepted for publication. 20 Jan 2022 Review of Review Editor 1 finalized. 07 Jan 2022 Review of Review Editor 2 finalized. You posted new comments. You posted new comments. Associate Editor Terry Francis Davies reactivated the review of Review Editor 2. Associate Editor Terry Francis Davies reactivated the review of Review Editor 1. 06 Jan 2022 Review of Review Editor 2 finalized. Submitting Author re-submitted manuscript. 19 Dec 2021 Interactive review forum activated automatically. 02 Dec 2021 Review of Reviewer 1 is finalized. 16 Nov 2021 Submitting Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d5d45263398, createdName=Q.Aur., createdTime=Fri Jan 21 16:59:27 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095540, encodeId=db20209554054, content=最近太慢了，最后一步，都快一个月了，杂志社放假了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c84b1734099, createdName=1def4ad2m75(暂无匿称), createdTime=Sun Oct 23 16:22:06 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106133, encodeId=be1a210613317, content=审稿速度:1.0 偏重的研究方向：糖尿病 经验分享：为什么我先被接受了，钱都交了，然后被拒了啊………… This manuscript does not fulfill the standards established for the journal to be considered for publication, and according to Frontiers policies (https://www***ontiersin.org/guidelines/policies-and-publication-ethics#AuthorshipAuthorResponsibilities), the article is being rejected. This decision applies across all Frontiers journals and is final., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKa9zsBsxXW560WZZQCmZVjdWtyppuKqGNgErY8TwOXAMx9Q53X4PRT2QdmNuTvHyJfzcicyDNqMUQ/132, createdBy=8bfe5305985, createdName=大仑丁, createdTime=Thu Dec 15 07:13:07 CST 2022, time=2022-12-15, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1077238, encodeId=441610e7238aa, content=偏重的研究方向：临床 经验分享：请问各位，一审两个审稿人提了一些小问题，但均直接endorse了，现在review finalized六天了，请问我能催下吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=969f5129926, createdName=1465389cm38暂无昵称, createdTime=Mon Dec 06 07:57:57 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974605, encodeId=f03a9e460516, content=审稿速度:2.0 经验分享：现在Frontiers都这么慢了吗，那比非OA的还有什么优势？6月9日投稿，到6月18还没有分配编辑……请问大家都是多久分配编辑呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7a851992297, createdName=1e1a9f0am26(暂无匿称), createdTime=Fri Jun 18 09:50:06 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882877, encodeId=20888828e745, content=我的一篇投稿frongtier in endocri，审了一个月回来了，两个reviewer，一个REVIEW 建议 substantial revision, 一个建议发表，这个substantial revision 是major 的意思吗？还是大大修？这种分歧很大的修完后接受的几率有多大？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92de2526374, createdName=124eece7m49(暂无昵称), createdTime=Sat Sep 05 08:09:33 CST 2020, time=2020-09-05, status=1, ipAttribution=)]

2023-12-26 ms2000000984739514 来自浙江省

审稿速度:2.0 | 投稿命中率:50.0
经验分享：有人碰到过这种拒稿理由吗？投稿过程中唯一异常的地方是杂志要求把原始数据上传到公共数据平台，我选择的暂未上传，不知道是不是因为这个原因被拒稿，按理说原始数据链接可以后面再补上，不造是不是变相拒稿。。。。。
2023.12.14 submit
2023.12.19 reject
The reason for this decision is:
Ethical issues or Integrity concerns, or other breach of policy were identified in this manuscript that prevent further review or publication.

87 14

展开14条回复

[GetPortalCommentsPageByObjectIdResponse(id=1218440, encodeId=dedb12184408c, content=审稿速度:1.0 偏重的研究方向：糖尿病 经验分享：请问各位大神，4月1号投，4.20邮件发过来说第1个审稿人意见上传了，提了十条意见，评分4345。说等第2个审稿人意见才能在系统上修改，目前一直没有第2个审稿人意见。有人类似吗？下一步该催稿还是等？<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=258, replyNumber=32, topicName=null, topicId=null, topicList=[TopicDto(id=76652, encryptionId=4f77e665253, topicName=糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0efd5705923, createdName=ms5000001229631335, createdTime=Tue May 10 13:46:10 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199310, encodeId=c0bc119931057, content=偏重的研究方向：糖尿病 经验分享：各位大佬我想问一下上个月投稿了该杂志状态一直都是“Your manuscript has been submitted and is now in the editorial assignment stage. We are in the process of appointing an editor and reviewers.”始终没有分配编辑，这种情况正常吗？或许该不该催一下呢？<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a><a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a><a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=526, replyNumber=16, topicName=null, topicId=null, topicList=[TopicDto(id=76652, encryptionId=4f77e665253, topicName=糖尿病), TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习), TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220304/ec265085fc77472b994925ad492adddb/3675981d0d3549d7b0fecbaa57f44ce0.jpg, createdBy=dbca6432415, createdName=ms8000000593527714, createdTime=Fri Mar 04 09:48:06 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220790, encodeId=4c6d1220e903b, content=偏重的研究方向：内分泌;Endocrinology 经验分享：大家好请问家人们在 initial validation等待了多久哈 4.27投稿等到现在还在这一步正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=234b5498982, createdName=ms6000001522264603, createdTime=Wed May 18 22:34:10 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177288, encodeId=34aa21e728837, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：有人碰到过这种拒稿理由吗？投稿过程中唯一异常的地方是杂志要求把原始数据上传到公共数据平台，我选择的暂未上传，不知道是不是因为这个原因被拒稿，按理说原始数据链接可以后面再补上，不造是不是变相拒稿。。。。。 2023.12.14 submit 2023.12.19 reject The reason for this decision is: Ethical issues or Integrity concerns, or other breach of policy were identified in this manuscript that prevent further review or publication., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db655482134, createdName=ms2000000984739514, createdTime=Tue Dec 26 15:07:37 CST 2023, time=2023-12-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1186886, encodeId=890311868868e, content=审稿速度:2.0 | 投稿命中率:50.0 | 版面费用:18000.0 经验分享： Date Updates 21 Jan 2022 Article accepted for publication. 20 Jan 2022 Review of Review Editor 1 finalized. 07 Jan 2022 Review of Review Editor 2 finalized. You posted new comments. You posted new comments. Associate Editor Terry Francis Davies reactivated the review of Review Editor 2. Associate Editor Terry Francis Davies reactivated the review of Review Editor 1. 06 Jan 2022 Review of Review Editor 2 finalized. Submitting Author re-submitted manuscript. 19 Dec 2021 Interactive review forum activated automatically. 02 Dec 2021 Review of Reviewer 1 is finalized. 16 Nov 2021 Submitting Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d5d45263398, createdName=Q.Aur., createdTime=Fri Jan 21 16:59:27 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095540, encodeId=db20209554054, content=最近太慢了，最后一步，都快一个月了，杂志社放假了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c84b1734099, createdName=1def4ad2m75(暂无匿称), createdTime=Sun Oct 23 16:22:06 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106133, encodeId=be1a210613317, content=审稿速度:1.0 偏重的研究方向：糖尿病 经验分享：为什么我先被接受了，钱都交了，然后被拒了啊………… This manuscript does not fulfill the standards established for the journal to be considered for publication, and according to Frontiers policies (https://www***ontiersin.org/guidelines/policies-and-publication-ethics#AuthorshipAuthorResponsibilities), the article is being rejected. This decision applies across all Frontiers journals and is final., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKa9zsBsxXW560WZZQCmZVjdWtyppuKqGNgErY8TwOXAMx9Q53X4PRT2QdmNuTvHyJfzcicyDNqMUQ/132, createdBy=8bfe5305985, createdName=大仑丁, createdTime=Thu Dec 15 07:13:07 CST 2022, time=2022-12-15, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1077238, encodeId=441610e7238aa, content=偏重的研究方向：临床 经验分享：请问各位，一审两个审稿人提了一些小问题，但均直接endorse了，现在review finalized六天了，请问我能催下吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=969f5129926, createdName=1465389cm38暂无昵称, createdTime=Mon Dec 06 07:57:57 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974605, encodeId=f03a9e460516, content=审稿速度:2.0 经验分享：现在Frontiers都这么慢了吗，那比非OA的还有什么优势？6月9日投稿，到6月18还没有分配编辑……请问大家都是多久分配编辑呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7a851992297, createdName=1e1a9f0am26(暂无匿称), createdTime=Fri Jun 18 09:50:06 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882877, encodeId=20888828e745, content=我的一篇投稿frongtier in endocri，审了一个月回来了，两个reviewer，一个REVIEW 建议 substantial revision, 一个建议发表，这个substantial revision 是major 的意思吗？还是大大修？这种分歧很大的修完后接受的几率有多大？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92de2526374, createdName=124eece7m49(暂无昵称), createdTime=Sat Sep 05 08:09:33 CST 2020, time=2020-09-05, status=1, ipAttribution=)]

2022-01-21 Q.Aur.

审稿速度:2.0 | 投稿命中率:50.0 | 版面费用:18000.0
经验分享：
Date Updates
21 Jan 2022
Article accepted for publication.
20 Jan 2022
Review of Review Editor 1 finalized.
07 Jan 2022
Review of Review Editor 2 finalized.
You posted new comments.
You posted new comments.
Associate Editor Terry Francis Davies reactivated the review of Review Editor 2.
Associate Editor Terry Francis Davies reactivated the review of Review Editor 1.
06 Jan 2022
Review of Review Editor 2 finalized.
Submitting Author re-submitted manuscript.
19 Dec 2021
Interactive review forum activated automatically.
02 Dec 2021
Review of Reviewer 1 is finalized.
16 Nov 2021
Submitting Author submitted manuscript.

142 14

展开14条回复

[GetPortalCommentsPageByObjectIdResponse(id=1218440, encodeId=dedb12184408c, content=审稿速度:1.0 偏重的研究方向：糖尿病 经验分享：请问各位大神，4月1号投，4.20邮件发过来说第1个审稿人意见上传了，提了十条意见，评分4345。说等第2个审稿人意见才能在系统上修改，目前一直没有第2个审稿人意见。有人类似吗？下一步该催稿还是等？<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=258, replyNumber=32, topicName=null, topicId=null, topicList=[TopicDto(id=76652, encryptionId=4f77e665253, topicName=糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0efd5705923, createdName=ms5000001229631335, createdTime=Tue May 10 13:46:10 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199310, encodeId=c0bc119931057, content=偏重的研究方向：糖尿病 经验分享：各位大佬我想问一下上个月投稿了该杂志状态一直都是“Your manuscript has been submitted and is now in the editorial assignment stage. We are in the process of appointing an editor and reviewers.”始终没有分配编辑，这种情况正常吗？或许该不该催一下呢？<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a><a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a><a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=526, replyNumber=16, topicName=null, topicId=null, topicList=[TopicDto(id=76652, encryptionId=4f77e665253, topicName=糖尿病), TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习), TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220304/ec265085fc77472b994925ad492adddb/3675981d0d3549d7b0fecbaa57f44ce0.jpg, createdBy=dbca6432415, createdName=ms8000000593527714, createdTime=Fri Mar 04 09:48:06 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220790, encodeId=4c6d1220e903b, content=偏重的研究方向：内分泌;Endocrinology 经验分享：大家好请问家人们在 initial validation等待了多久哈 4.27投稿等到现在还在这一步正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=234b5498982, createdName=ms6000001522264603, createdTime=Wed May 18 22:34:10 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177288, encodeId=34aa21e728837, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：有人碰到过这种拒稿理由吗？投稿过程中唯一异常的地方是杂志要求把原始数据上传到公共数据平台，我选择的暂未上传，不知道是不是因为这个原因被拒稿，按理说原始数据链接可以后面再补上，不造是不是变相拒稿。。。。。 2023.12.14 submit 2023.12.19 reject The reason for this decision is: Ethical issues or Integrity concerns, or other breach of policy were identified in this manuscript that prevent further review or publication., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db655482134, createdName=ms2000000984739514, createdTime=Tue Dec 26 15:07:37 CST 2023, time=2023-12-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1186886, encodeId=890311868868e, content=审稿速度:2.0 | 投稿命中率:50.0 | 版面费用:18000.0 经验分享： Date Updates 21 Jan 2022 Article accepted for publication. 20 Jan 2022 Review of Review Editor 1 finalized. 07 Jan 2022 Review of Review Editor 2 finalized. You posted new comments. You posted new comments. Associate Editor Terry Francis Davies reactivated the review of Review Editor 2. Associate Editor Terry Francis Davies reactivated the review of Review Editor 1. 06 Jan 2022 Review of Review Editor 2 finalized. Submitting Author re-submitted manuscript. 19 Dec 2021 Interactive review forum activated automatically. 02 Dec 2021 Review of Reviewer 1 is finalized. 16 Nov 2021 Submitting Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d5d45263398, createdName=Q.Aur., createdTime=Fri Jan 21 16:59:27 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095540, encodeId=db20209554054, content=最近太慢了，最后一步，都快一个月了，杂志社放假了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c84b1734099, createdName=1def4ad2m75(暂无匿称), createdTime=Sun Oct 23 16:22:06 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106133, encodeId=be1a210613317, content=审稿速度:1.0 偏重的研究方向：糖尿病 经验分享：为什么我先被接受了，钱都交了，然后被拒了啊………… This manuscript does not fulfill the standards established for the journal to be considered for publication, and according to Frontiers policies (https://www***ontiersin.org/guidelines/policies-and-publication-ethics#AuthorshipAuthorResponsibilities), the article is being rejected. This decision applies across all Frontiers journals and is final., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKa9zsBsxXW560WZZQCmZVjdWtyppuKqGNgErY8TwOXAMx9Q53X4PRT2QdmNuTvHyJfzcicyDNqMUQ/132, createdBy=8bfe5305985, createdName=大仑丁, createdTime=Thu Dec 15 07:13:07 CST 2022, time=2022-12-15, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1077238, encodeId=441610e7238aa, content=偏重的研究方向：临床 经验分享：请问各位，一审两个审稿人提了一些小问题，但均直接endorse了，现在review finalized六天了，请问我能催下吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=969f5129926, createdName=1465389cm38暂无昵称, createdTime=Mon Dec 06 07:57:57 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974605, encodeId=f03a9e460516, content=审稿速度:2.0 经验分享：现在Frontiers都这么慢了吗，那比非OA的还有什么优势？6月9日投稿，到6月18还没有分配编辑……请问大家都是多久分配编辑呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7a851992297, createdName=1e1a9f0am26(暂无匿称), createdTime=Fri Jun 18 09:50:06 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882877, encodeId=20888828e745, content=我的一篇投稿frongtier in endocri，审了一个月回来了，两个reviewer，一个REVIEW 建议 substantial revision, 一个建议发表，这个substantial revision 是major 的意思吗？还是大大修？这种分歧很大的修完后接受的几率有多大？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92de2526374, createdName=124eece7m49(暂无昵称), createdTime=Sat Sep 05 08:09:33 CST 2020, time=2020-09-05, status=1, ipAttribution=)]

2022-10-23 1def4ad2m75(暂无匿称)

最近太慢了，最后一步，都快一个月了，杂志社放假了吗

84 14

展开14条回复

[GetPortalCommentsPageByObjectIdResponse(id=1218440, encodeId=dedb12184408c, content=审稿速度:1.0 偏重的研究方向：糖尿病 经验分享：请问各位大神，4月1号投，4.20邮件发过来说第1个审稿人意见上传了，提了十条意见，评分4345。说等第2个审稿人意见才能在系统上修改，目前一直没有第2个审稿人意见。有人类似吗？下一步该催稿还是等？<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=258, replyNumber=32, topicName=null, topicId=null, topicList=[TopicDto(id=76652, encryptionId=4f77e665253, topicName=糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0efd5705923, createdName=ms5000001229631335, createdTime=Tue May 10 13:46:10 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199310, encodeId=c0bc119931057, content=偏重的研究方向：糖尿病 经验分享：各位大佬我想问一下上个月投稿了该杂志状态一直都是“Your manuscript has been submitted and is now in the editorial assignment stage. We are in the process of appointing an editor and reviewers.”始终没有分配编辑，这种情况正常吗？或许该不该催一下呢？<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a><a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a><a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=526, replyNumber=16, topicName=null, topicId=null, topicList=[TopicDto(id=76652, encryptionId=4f77e665253, topicName=糖尿病), TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习), TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220304/ec265085fc77472b994925ad492adddb/3675981d0d3549d7b0fecbaa57f44ce0.jpg, createdBy=dbca6432415, createdName=ms8000000593527714, createdTime=Fri Mar 04 09:48:06 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220790, encodeId=4c6d1220e903b, content=偏重的研究方向：内分泌;Endocrinology 经验分享：大家好请问家人们在 initial validation等待了多久哈 4.27投稿等到现在还在这一步正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=234b5498982, createdName=ms6000001522264603, createdTime=Wed May 18 22:34:10 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177288, encodeId=34aa21e728837, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：有人碰到过这种拒稿理由吗？投稿过程中唯一异常的地方是杂志要求把原始数据上传到公共数据平台，我选择的暂未上传，不知道是不是因为这个原因被拒稿，按理说原始数据链接可以后面再补上，不造是不是变相拒稿。。。。。 2023.12.14 submit 2023.12.19 reject The reason for this decision is: Ethical issues or Integrity concerns, or other breach of policy were identified in this manuscript that prevent further review or publication., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db655482134, createdName=ms2000000984739514, createdTime=Tue Dec 26 15:07:37 CST 2023, time=2023-12-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1186886, encodeId=890311868868e, content=审稿速度:2.0 | 投稿命中率:50.0 | 版面费用:18000.0 经验分享： Date Updates 21 Jan 2022 Article accepted for publication. 20 Jan 2022 Review of Review Editor 1 finalized. 07 Jan 2022 Review of Review Editor 2 finalized. You posted new comments. You posted new comments. Associate Editor Terry Francis Davies reactivated the review of Review Editor 2. Associate Editor Terry Francis Davies reactivated the review of Review Editor 1. 06 Jan 2022 Review of Review Editor 2 finalized. Submitting Author re-submitted manuscript. 19 Dec 2021 Interactive review forum activated automatically. 02 Dec 2021 Review of Reviewer 1 is finalized. 16 Nov 2021 Submitting Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d5d45263398, createdName=Q.Aur., createdTime=Fri Jan 21 16:59:27 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095540, encodeId=db20209554054, content=最近太慢了，最后一步，都快一个月了，杂志社放假了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c84b1734099, createdName=1def4ad2m75(暂无匿称), createdTime=Sun Oct 23 16:22:06 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106133, encodeId=be1a210613317, content=审稿速度:1.0 偏重的研究方向：糖尿病 经验分享：为什么我先被接受了，钱都交了，然后被拒了啊………… This manuscript does not fulfill the standards established for the journal to be considered for publication, and according to Frontiers policies (https://www***ontiersin.org/guidelines/policies-and-publication-ethics#AuthorshipAuthorResponsibilities), the article is being rejected. This decision applies across all Frontiers journals and is final., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKa9zsBsxXW560WZZQCmZVjdWtyppuKqGNgErY8TwOXAMx9Q53X4PRT2QdmNuTvHyJfzcicyDNqMUQ/132, createdBy=8bfe5305985, createdName=大仑丁, createdTime=Thu Dec 15 07:13:07 CST 2022, time=2022-12-15, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1077238, encodeId=441610e7238aa, content=偏重的研究方向：临床 经验分享：请问各位，一审两个审稿人提了一些小问题，但均直接endorse了，现在review finalized六天了，请问我能催下吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=969f5129926, createdName=1465389cm38暂无昵称, createdTime=Mon Dec 06 07:57:57 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974605, encodeId=f03a9e460516, content=审稿速度:2.0 经验分享：现在Frontiers都这么慢了吗，那比非OA的还有什么优势？6月9日投稿，到6月18还没有分配编辑……请问大家都是多久分配编辑呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7a851992297, createdName=1e1a9f0am26(暂无匿称), createdTime=Fri Jun 18 09:50:06 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882877, encodeId=20888828e745, content=我的一篇投稿frongtier in endocri，审了一个月回来了，两个reviewer，一个REVIEW 建议 substantial revision, 一个建议发表，这个substantial revision 是major 的意思吗？还是大大修？这种分歧很大的修完后接受的几率有多大？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92de2526374, createdName=124eece7m49(暂无昵称), createdTime=Sat Sep 05 08:09:33 CST 2020, time=2020-09-05, status=1, ipAttribution=)]

2022-12-15 大仑丁来自湖北省

审稿速度:1.0
偏重的研究方向：糖尿病
经验分享：为什么我先被接受了，钱都交了，然后被拒了啊………… This manuscript does not fulfill the standards established for the journal to be considered for publication, and according to Frontiers policies (https://www***ontiersin.org/guidelines/policies-and-publication-ethics#AuthorshipAuthorResponsibilities), the article is being rejected. This decision applies across all Frontiers journals and is final.

128 13

展开13条回复

[GetPortalCommentsPageByObjectIdResponse(id=1218440, encodeId=dedb12184408c, content=审稿速度:1.0 偏重的研究方向：糖尿病 经验分享：请问各位大神，4月1号投，4.20邮件发过来说第1个审稿人意见上传了，提了十条意见，评分4345。说等第2个审稿人意见才能在系统上修改，目前一直没有第2个审稿人意见。有人类似吗？下一步该催稿还是等？<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=258, replyNumber=32, topicName=null, topicId=null, topicList=[TopicDto(id=76652, encryptionId=4f77e665253, topicName=糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0efd5705923, createdName=ms5000001229631335, createdTime=Tue May 10 13:46:10 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199310, encodeId=c0bc119931057, content=偏重的研究方向：糖尿病 经验分享：各位大佬我想问一下上个月投稿了该杂志状态一直都是“Your manuscript has been submitted and is now in the editorial assignment stage. We are in the process of appointing an editor and reviewers.”始终没有分配编辑，这种情况正常吗？或许该不该催一下呢？<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a><a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a><a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=526, replyNumber=16, topicName=null, topicId=null, topicList=[TopicDto(id=76652, encryptionId=4f77e665253, topicName=糖尿病), TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习), TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220304/ec265085fc77472b994925ad492adddb/3675981d0d3549d7b0fecbaa57f44ce0.jpg, createdBy=dbca6432415, createdName=ms8000000593527714, createdTime=Fri Mar 04 09:48:06 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220790, encodeId=4c6d1220e903b, content=偏重的研究方向：内分泌;Endocrinology 经验分享：大家好请问家人们在 initial validation等待了多久哈 4.27投稿等到现在还在这一步正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=234b5498982, createdName=ms6000001522264603, createdTime=Wed May 18 22:34:10 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177288, encodeId=34aa21e728837, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：有人碰到过这种拒稿理由吗？投稿过程中唯一异常的地方是杂志要求把原始数据上传到公共数据平台，我选择的暂未上传，不知道是不是因为这个原因被拒稿，按理说原始数据链接可以后面再补上，不造是不是变相拒稿。。。。。 2023.12.14 submit 2023.12.19 reject The reason for this decision is: Ethical issues or Integrity concerns, or other breach of policy were identified in this manuscript that prevent further review or publication., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db655482134, createdName=ms2000000984739514, createdTime=Tue Dec 26 15:07:37 CST 2023, time=2023-12-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1186886, encodeId=890311868868e, content=审稿速度:2.0 | 投稿命中率:50.0 | 版面费用:18000.0 经验分享： Date Updates 21 Jan 2022 Article accepted for publication. 20 Jan 2022 Review of Review Editor 1 finalized. 07 Jan 2022 Review of Review Editor 2 finalized. You posted new comments. You posted new comments. Associate Editor Terry Francis Davies reactivated the review of Review Editor 2. Associate Editor Terry Francis Davies reactivated the review of Review Editor 1. 06 Jan 2022 Review of Review Editor 2 finalized. Submitting Author re-submitted manuscript. 19 Dec 2021 Interactive review forum activated automatically. 02 Dec 2021 Review of Reviewer 1 is finalized. 16 Nov 2021 Submitting Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d5d45263398, createdName=Q.Aur., createdTime=Fri Jan 21 16:59:27 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095540, encodeId=db20209554054, content=最近太慢了，最后一步，都快一个月了，杂志社放假了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c84b1734099, createdName=1def4ad2m75(暂无匿称), createdTime=Sun Oct 23 16:22:06 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106133, encodeId=be1a210613317, content=审稿速度:1.0 偏重的研究方向：糖尿病 经验分享：为什么我先被接受了，钱都交了，然后被拒了啊………… This manuscript does not fulfill the standards established for the journal to be considered for publication, and according to Frontiers policies (https://www***ontiersin.org/guidelines/policies-and-publication-ethics#AuthorshipAuthorResponsibilities), the article is being rejected. This decision applies across all Frontiers journals and is final., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKa9zsBsxXW560WZZQCmZVjdWtyppuKqGNgErY8TwOXAMx9Q53X4PRT2QdmNuTvHyJfzcicyDNqMUQ/132, createdBy=8bfe5305985, createdName=大仑丁, createdTime=Thu Dec 15 07:13:07 CST 2022, time=2022-12-15, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1077238, encodeId=441610e7238aa, content=偏重的研究方向：临床 经验分享：请问各位，一审两个审稿人提了一些小问题，但均直接endorse了，现在review finalized六天了，请问我能催下吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=969f5129926, createdName=1465389cm38暂无昵称, createdTime=Mon Dec 06 07:57:57 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974605, encodeId=f03a9e460516, content=审稿速度:2.0 经验分享：现在Frontiers都这么慢了吗，那比非OA的还有什么优势？6月9日投稿，到6月18还没有分配编辑……请问大家都是多久分配编辑呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7a851992297, createdName=1e1a9f0am26(暂无匿称), createdTime=Fri Jun 18 09:50:06 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882877, encodeId=20888828e745, content=我的一篇投稿frongtier in endocri，审了一个月回来了，两个reviewer，一个REVIEW 建议 substantial revision, 一个建议发表，这个substantial revision 是major 的意思吗？还是大大修？这种分歧很大的修完后接受的几率有多大？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92de2526374, createdName=124eece7m49(暂无昵称), createdTime=Sat Sep 05 08:09:33 CST 2020, time=2020-09-05, status=1, ipAttribution=)]

2021-12-06 1465389cm38暂无昵称

偏重的研究方向：临床
经验分享：请问各位，一审两个审稿人提了一些小问题，但均直接endorse了，现在review finalized六天了，请问我能催下吗？

139 13

展开13条回复

[GetPortalCommentsPageByObjectIdResponse(id=1218440, encodeId=dedb12184408c, content=审稿速度:1.0 偏重的研究方向：糖尿病 经验分享：请问各位大神，4月1号投，4.20邮件发过来说第1个审稿人意见上传了，提了十条意见，评分4345。说等第2个审稿人意见才能在系统上修改，目前一直没有第2个审稿人意见。有人类似吗？下一步该催稿还是等？<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=258, replyNumber=32, topicName=null, topicId=null, topicList=[TopicDto(id=76652, encryptionId=4f77e665253, topicName=糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0efd5705923, createdName=ms5000001229631335, createdTime=Tue May 10 13:46:10 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199310, encodeId=c0bc119931057, content=偏重的研究方向：糖尿病 经验分享：各位大佬我想问一下上个月投稿了该杂志状态一直都是“Your manuscript has been submitted and is now in the editorial assignment stage. We are in the process of appointing an editor and reviewers.”始终没有分配编辑，这种情况正常吗？或许该不该催一下呢？<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a><a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a><a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=526, replyNumber=16, topicName=null, topicId=null, topicList=[TopicDto(id=76652, encryptionId=4f77e665253, topicName=糖尿病), TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习), TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220304/ec265085fc77472b994925ad492adddb/3675981d0d3549d7b0fecbaa57f44ce0.jpg, createdBy=dbca6432415, createdName=ms8000000593527714, createdTime=Fri Mar 04 09:48:06 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220790, encodeId=4c6d1220e903b, content=偏重的研究方向：内分泌;Endocrinology 经验分享：大家好请问家人们在 initial validation等待了多久哈 4.27投稿等到现在还在这一步正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=234b5498982, createdName=ms6000001522264603, createdTime=Wed May 18 22:34:10 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177288, encodeId=34aa21e728837, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：有人碰到过这种拒稿理由吗？投稿过程中唯一异常的地方是杂志要求把原始数据上传到公共数据平台，我选择的暂未上传，不知道是不是因为这个原因被拒稿，按理说原始数据链接可以后面再补上，不造是不是变相拒稿。。。。。 2023.12.14 submit 2023.12.19 reject The reason for this decision is: Ethical issues or Integrity concerns, or other breach of policy were identified in this manuscript that prevent further review or publication., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db655482134, createdName=ms2000000984739514, createdTime=Tue Dec 26 15:07:37 CST 2023, time=2023-12-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1186886, encodeId=890311868868e, content=审稿速度:2.0 | 投稿命中率:50.0 | 版面费用:18000.0 经验分享： Date Updates 21 Jan 2022 Article accepted for publication. 20 Jan 2022 Review of Review Editor 1 finalized. 07 Jan 2022 Review of Review Editor 2 finalized. You posted new comments. You posted new comments. Associate Editor Terry Francis Davies reactivated the review of Review Editor 2. Associate Editor Terry Francis Davies reactivated the review of Review Editor 1. 06 Jan 2022 Review of Review Editor 2 finalized. Submitting Author re-submitted manuscript. 19 Dec 2021 Interactive review forum activated automatically. 02 Dec 2021 Review of Reviewer 1 is finalized. 16 Nov 2021 Submitting Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d5d45263398, createdName=Q.Aur., createdTime=Fri Jan 21 16:59:27 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095540, encodeId=db20209554054, content=最近太慢了，最后一步，都快一个月了，杂志社放假了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c84b1734099, createdName=1def4ad2m75(暂无匿称), createdTime=Sun Oct 23 16:22:06 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106133, encodeId=be1a210613317, content=审稿速度:1.0 偏重的研究方向：糖尿病 经验分享：为什么我先被接受了，钱都交了，然后被拒了啊………… This manuscript does not fulfill the standards established for the journal to be considered for publication, and according to Frontiers policies (https://www***ontiersin.org/guidelines/policies-and-publication-ethics#AuthorshipAuthorResponsibilities), the article is being rejected. This decision applies across all Frontiers journals and is final., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKa9zsBsxXW560WZZQCmZVjdWtyppuKqGNgErY8TwOXAMx9Q53X4PRT2QdmNuTvHyJfzcicyDNqMUQ/132, createdBy=8bfe5305985, createdName=大仑丁, createdTime=Thu Dec 15 07:13:07 CST 2022, time=2022-12-15, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1077238, encodeId=441610e7238aa, content=偏重的研究方向：临床 经验分享：请问各位，一审两个审稿人提了一些小问题，但均直接endorse了，现在review finalized六天了，请问我能催下吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=969f5129926, createdName=1465389cm38暂无昵称, createdTime=Mon Dec 06 07:57:57 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974605, encodeId=f03a9e460516, content=审稿速度:2.0 经验分享：现在Frontiers都这么慢了吗，那比非OA的还有什么优势？6月9日投稿，到6月18还没有分配编辑……请问大家都是多久分配编辑呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7a851992297, createdName=1e1a9f0am26(暂无匿称), createdTime=Fri Jun 18 09:50:06 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882877, encodeId=20888828e745, content=我的一篇投稿frongtier in endocri，审了一个月回来了，两个reviewer，一个REVIEW 建议 substantial revision, 一个建议发表，这个substantial revision 是major 的意思吗？还是大大修？这种分歧很大的修完后接受的几率有多大？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92de2526374, createdName=124eece7m49(暂无昵称), createdTime=Sat Sep 05 08:09:33 CST 2020, time=2020-09-05, status=1, ipAttribution=)]

2021-06-18 1e1a9f0am26(暂无匿称)

审稿速度:2.0
经验分享：现在Frontiers都这么慢了吗，那比非OA的还有什么优势？6月9日投稿，到6月18还没有分配编辑……请问大家都是多久分配编辑呀？

58 13

展开13条回复

[GetPortalCommentsPageByObjectIdResponse(id=1218440, encodeId=dedb12184408c, content=审稿速度:1.0 偏重的研究方向：糖尿病 经验分享：请问各位大神，4月1号投，4.20邮件发过来说第1个审稿人意见上传了，提了十条意见，评分4345。说等第2个审稿人意见才能在系统上修改，目前一直没有第2个审稿人意见。有人类似吗？下一步该催稿还是等？<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=258, replyNumber=32, topicName=null, topicId=null, topicList=[TopicDto(id=76652, encryptionId=4f77e665253, topicName=糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0efd5705923, createdName=ms5000001229631335, createdTime=Tue May 10 13:46:10 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199310, encodeId=c0bc119931057, content=偏重的研究方向：糖尿病 经验分享：各位大佬我想问一下上个月投稿了该杂志状态一直都是“Your manuscript has been submitted and is now in the editorial assignment stage. We are in the process of appointing an editor and reviewers.”始终没有分配编辑，这种情况正常吗？或许该不该催一下呢？<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a><a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a><a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=526, replyNumber=16, topicName=null, topicId=null, topicList=[TopicDto(id=76652, encryptionId=4f77e665253, topicName=糖尿病), TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习), TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220304/ec265085fc77472b994925ad492adddb/3675981d0d3549d7b0fecbaa57f44ce0.jpg, createdBy=dbca6432415, createdName=ms8000000593527714, createdTime=Fri Mar 04 09:48:06 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220790, encodeId=4c6d1220e903b, content=偏重的研究方向：内分泌;Endocrinology 经验分享：大家好请问家人们在 initial validation等待了多久哈 4.27投稿等到现在还在这一步正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=16, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=234b5498982, createdName=ms6000001522264603, createdTime=Wed May 18 22:34:10 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177288, encodeId=34aa21e728837, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：有人碰到过这种拒稿理由吗？投稿过程中唯一异常的地方是杂志要求把原始数据上传到公共数据平台，我选择的暂未上传，不知道是不是因为这个原因被拒稿，按理说原始数据链接可以后面再补上，不造是不是变相拒稿。。。。。 2023.12.14 submit 2023.12.19 reject The reason for this decision is: Ethical issues or Integrity concerns, or other breach of policy were identified in this manuscript that prevent further review or publication., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db655482134, createdName=ms2000000984739514, createdTime=Tue Dec 26 15:07:37 CST 2023, time=2023-12-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1186886, encodeId=890311868868e, content=审稿速度:2.0 | 投稿命中率:50.0 | 版面费用:18000.0 经验分享： Date Updates 21 Jan 2022 Article accepted for publication. 20 Jan 2022 Review of Review Editor 1 finalized. 07 Jan 2022 Review of Review Editor 2 finalized. You posted new comments. You posted new comments. Associate Editor Terry Francis Davies reactivated the review of Review Editor 2. Associate Editor Terry Francis Davies reactivated the review of Review Editor 1. 06 Jan 2022 Review of Review Editor 2 finalized. Submitting Author re-submitted manuscript. 19 Dec 2021 Interactive review forum activated automatically. 02 Dec 2021 Review of Reviewer 1 is finalized. 16 Nov 2021 Submitting Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d5d45263398, createdName=Q.Aur., createdTime=Fri Jan 21 16:59:27 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095540, encodeId=db20209554054, content=最近太慢了，最后一步，都快一个月了，杂志社放假了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c84b1734099, createdName=1def4ad2m75(暂无匿称), createdTime=Sun Oct 23 16:22:06 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106133, encodeId=be1a210613317, content=审稿速度:1.0 偏重的研究方向：糖尿病 经验分享：为什么我先被接受了，钱都交了，然后被拒了啊………… This manuscript does not fulfill the standards established for the journal to be considered for publication, and according to Frontiers policies (https://www***ontiersin.org/guidelines/policies-and-publication-ethics#AuthorshipAuthorResponsibilities), the article is being rejected. This decision applies across all Frontiers journals and is final., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKa9zsBsxXW560WZZQCmZVjdWtyppuKqGNgErY8TwOXAMx9Q53X4PRT2QdmNuTvHyJfzcicyDNqMUQ/132, createdBy=8bfe5305985, createdName=大仑丁, createdTime=Thu Dec 15 07:13:07 CST 2022, time=2022-12-15, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1077238, encodeId=441610e7238aa, content=偏重的研究方向：临床 经验分享：请问各位，一审两个审稿人提了一些小问题，但均直接endorse了，现在review finalized六天了，请问我能催下吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=969f5129926, createdName=1465389cm38暂无昵称, createdTime=Mon Dec 06 07:57:57 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974605, encodeId=f03a9e460516, content=审稿速度:2.0 经验分享：现在Frontiers都这么慢了吗，那比非OA的还有什么优势？6月9日投稿，到6月18还没有分配编辑……请问大家都是多久分配编辑呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7a851992297, createdName=1e1a9f0am26(暂无匿称), createdTime=Fri Jun 18 09:50:06 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882877, encodeId=20888828e745, content=我的一篇投稿frongtier in endocri，审了一个月回来了，两个reviewer，一个REVIEW 建议 substantial revision, 一个建议发表，这个substantial revision 是major 的意思吗？还是大大修？这种分歧很大的修完后接受的几率有多大？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92de2526374, createdName=124eece7m49(暂无昵称), createdTime=Sat Sep 05 08:09:33 CST 2020, time=2020-09-05, status=1, ipAttribution=)]

2020-09-05 124eece7m49(暂无昵称)

我的一篇投稿frongtier in endocri，审了一个月回来了，两个reviewer，一个REVIEW 建议 substantial revision, 一个建议发表，这个substantial revision 是major 的意思吗？还是大大修？这种分歧很大的修完后接受的几率有多大？

196 13

展开13条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务